Received: 13 March 2018
Accepted: 3 July 2018
First Online: 16 August 2018
Ethics approval and consent to participate
: This chart review assessed healthcare resource utilization by patients with hypophosphatasia at participating hospitals (Manchester University NHS Foundation Trust and Birmingham Women’s and Children’s Hospital in England). Informed consent was obtained from each patient and/or their family or guardian. Approval of the protocol was not required by an institutional review board or ethics committee for this type of study.
: Informed consent was obtained from each patient and/or their family or guardian.
: ABD has no conflict of interest to report.VS has received consulting fees for participation in advisory boards and honoraria as guest speaker by Alexion Pharmaceuticals, Inc.NS reports no conflict of interest.RY has received a consultant fee from Alexion Pharmaceuticals, Inc., for contributions to an advisory board.MZM has received fees/honoraria from Alexion Pharmaceuticals, Inc.RP is an investigator in Study ENB-010-10 (ClinicalTrials.gov Identifier: NCT01176266), which is sponsored by Alexion Pharmaceuticals, Inc., the license-holder for asfotase alfa, a therapeutic agent approved in multiple countries, including Australia, Canada, Europe, Japan, and the United States, for treatment of patients with pediatric-onset hypophosphatasia. RP has received consulting fees from Alexion for participation in advisory boards and as a speaker at satellite symposia.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.